Cargando…
Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies
Despite the introduction of many novel therapies into the clinic to target hematological malignancies, glucocorticoids (GCs) still remain one of the cornerstone drugs in first-line treatment of lymphoid tumors. However, a significant portion of the patients display acquired GC therapy resistance. Th...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992511/ https://www.ncbi.nlm.nih.gov/pubmed/35582582 http://dx.doi.org/10.20517/cdr.2019.29 |